ABAC Therapeutics is a technology company.
ABAC Therapeutics is a technology company.
ABAC Therapeutics has raised $20.0M across 1 funding round.
ABAC Therapeutics has raised $20.0M in total across 1 funding round.
ABAC Therapeutics is a biotech company developing novel antibiotics to combat antibiotic-resistant bacteria using its proprietary PasNas discovery platform. It targets pathogen-specific therapies that selectively kill multi-drug resistant pathogens, addressing a critical global health crisis where traditional broad-spectrum antibiotics fail.[3][4]
The company serves patients with severe infections from highly resistant bacteria, solving the problem of antimicrobial resistance (AMR) by creating low-resistance-risk antibiotics with improved safety profiles. Following a €16 million Series A funding round, ABAC shows strong growth momentum in early-stage biotech, positioning it to advance candidates into clinical development.[3][4]
ABAC Therapeutics emerged from the urgent need to tackle rising antibiotic resistance, leveraging its PasNas platform for precise antibiotic discovery. While specific founders are not detailed in available sources, the company is based in Switzerland, aligning with the region's biotech ecosystem, and raised €16 million in Series A financing to fuel its pipeline development—a pivotal moment signaling investor confidence in its approach.[3][4]
Early traction is marked by this funding, which supports progression of pathogen-specific antibiotics designed to minimize resistance development, building on innovations in selective targeting amid a backdrop of global AMR challenges.[3]
(Note: Search results distinguish ABAC Therapeutics from ABAC R&D AG, a separate Swiss firm focused on food ingredient processes; this analysis centers on the therapeutics entity.[1])
ABAC rides the antimicrobial resistance (AMR) trend, a pressing market force projected to cause 10 million annual deaths by 2050 if unchecked, driving demand for precision antibiotics. Its timing aligns with regulatory incentives like FDA Qualified Infectious Disease Product designation and EU funding for AMR innovations, favoring pathogen-specific drugs over outdated broad-spectrum ones.[3][4]
By influencing the biotech ecosystem, ABAC contributes to sustainable antibiotic pipelines, potentially reshaping infectious disease treatment amid declining pharma investment in this high-risk area.
ABAC is poised to advance PasNas-derived candidates into clinical trials, with €16 million fueling proof-of-concept studies against priority resistant pathogens. Trends like AI-enhanced discovery and global AMR collaborations will shape its path, potentially expanding influence through partnerships with big pharma seeking novel assets.
As antibiotic innovation lags, ABAC's selective-kill focus positions it as a frontrunner in revitalizing treatments for resistant infections, echoing its Series A momentum to deliver impactful therapies.
ABAC Therapeutics has raised $20.0M in total across 1 funding round.
ABAC Therapeutics's investors include Faber, Pontifax Venture Capital.
ABAC Therapeutics has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $20.0M Series A | Faber, Pontifax Venture Capital |